[Ser25] Protein Kinase C (19-31) Mechanism, Clinical Applica

[Ser25] Protein Kinase C (19-31): Mechanism, Clinical Applications, and Research Perspectives

Introduction
[Ser25] Protein Kinase C (19-31) is a synthetic peptide corresponding to amino acids 19 to 31 of the Protein Kinase C (PKC) regulatory domain, with a serine residue at position 25. PKC is a family of serine/threonine kinases that play pivotal roles in various cellular processes, including signal transduction, cell proliferation, differentiation, and apoptosis (Newton, 2018, J Biol Chem). The [Ser25] modification is of particular interest as phosphorylation at this site is implicated in the regulation of PKC activity and its downstream signaling pathways.

The [Ser25] PKC (19-31) peptide is utilized as a research tool to study PKC-mediated signaling, serving as a substrate or competitive inhibitor in biochemical assays. Its sequence, RKGALRQKNVHEVKN, mimics a critical region of the PKC regulatory domain, allowing for targeted investigation of PKC isoform-specific functions and interactions (ApexBio, 2024). The peptide’s design enables researchers to dissect the mechanistic underpinnings of PKC activation and its role in disease pathogenesis, especially in oncology, neuroscience, and immunology.

[Related: ITF2357 (Givinostat)] Clinical Value and Applications
The clinical value of [Ser25] PKC (19-31) lies in its utility as a molecular probe for elucidating PKC-dependent pathways implicated in human diseases. PKC isoforms are dysregulated in various pathological conditions, including cancer, neurodegenerative disorders, cardiovascular diseases, and immune dysfunctions (Steinberg, 2008, Nat Rev Mol Cell Biol). By modulating PKC activity in vitro, [Ser25] PKC (19-31) enables the identification of novel therapeutic targets and the validation of small molecule inhibitors or activators.

In oncology, aberrant PKC signaling contributes to tumorigenesis, metastasis, and resistance to chemotherapy (Antal et al., 2015, Cancer Lett). The peptide facilitates the study of PKC’s role in cell cycle regulation and apoptosis, providing insights into mechanisms of drug resistance and potential combination therapies. In neuroscience, PKC is involved in synaptic plasticity, memory formation, and neuroprotection (Nelson & Alkon, 2009, Trends Neurosci). [Ser25] PKC (19-31) is used to investigate the molecular basis of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.

[Related: zvad fmk] Furthermore, in immunology, PKC modulates T-cell activation, cytokine production, and inflammatory responses (Isakov, 2018, Front Immunol). The peptide serves as a tool to delineate PKC-dependent immune signaling, which is critical for the development of immunomodulatory therapies.

Key Challenges and Pain Points Addressed
Current research on PKC is hampered by the complexity of its isoforms, overlapping substrate specificities, and context-dependent functions. Traditional small molecule inhibitors often lack selectivity, leading to off-target effects and limited clinical efficacy (Griner & Kazanietz, 2007, Nat Rev Drug Discov). Additionally, the dynamic regulation of PKC by phosphorylation, localization, and protein-protein interactions complicates the interpretation of functional studies.

[Related: Valproic acid] [Ser25] PKC (19-31) addresses several of these challenges by providing a highly specific peptide substrate that can be used to monitor PKC activity in vitro and in cell-based assays. Its defined sequence and phosphorylation site enable precise mapping of PKC-mediated phosphorylation events, facilitating the identification of isoform-specific functions. The peptide also serves as a competitive inhibitor, allowing researchers to dissect the contribution of PKC to complex signaling networks without the confounding effects of non-specific inhibitors.

Moreover, the use of [Ser25] PKC (19-31) in high-throughput screening assays accelerates the discovery of novel PKC modulators, supporting drug development efforts in multiple therapeutic areas.

Literature Review
Several studies have highlighted the importance of PKC regulatory domains and the utility of synthetic peptides in PKC research:

1. Newton, A.C. (2018). Protein kinase C: perfectly balanced. J Biol Chem, 293(44), 17883-17896.
- This review discusses the structural and functional diversity of PKC isoforms, emphasizing the regulatory mechanisms involving phosphorylation sites such as Ser25.

2. Steinberg, S.F. (2008). Structural basis of protein kinase C isoform function. Nat Rev Mol Cell Biol, 9(12), 971-982.
- Steinberg provides a comprehensive overview of PKC structure-function relationships, highlighting the significance of regulatory domains and their role in disease.

3. Antal, C.E., et al. (2015). Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cancer Lett, 357(2), 467-476.
- This study demonstrates the dual role of PKC in cancer, where mutations in regulatory domains can either promote or suppress tumorigenesis.

4. Nelson, T.J., & Alkon, D.L. (2009). Protein kinase C (PKC) in memory, Alzheimer’s disease and aging. Trends Neurosci, 32(10), 517-527.
- The authors explore the involvement of PKC in cognitive processes and neurodegeneration, supporting the use of PKC-targeted peptides in neurological research.

5. Isakov, N. (2018). Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression. Front Immunol, 9, 937.
- Isakov reviews the immunological roles of PKC isoforms, underscoring the therapeutic potential of modulating PKC activity.

6. Griner, E.M., & Kazanietz, M.G. (2007). Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Drug Discov, 6(4), 281-295.
- This article discusses the challenges of targeting PKC in drug discovery and the need for more selective research tools.

7. Mochly-Rosen, D., & Das, K. (2012). Therapeutic potential of protein kinase C inhibitors and activators. Nat Rev Drug Discov, 11(12), 936-954.
- The review highlights the therapeutic implications of PKC modulation and the importance of peptide-based research tools.

Experimental Data and Results
Experimental studies utilizing [Ser25] PKC (19-31) have demonstrated its efficacy as a substrate and inhibitor in PKC assays. In vitro kinase assays show that the peptide is efficiently phosphorylated by conventional and novel PKC isoforms, with phosphorylation at Ser25 serving as a readout for PKC activity (Newton, 2018). The specificity of the peptide allows for discrimination between PKC isoforms and other serine/threonine kinases.

In cell-based assays, treatment with [Ser25] PKC (19-31) leads to dose-dependent inhibition of PKC-mediated phosphorylation of endogenous substrates, confirming its utility as a competitive inhibitor (Steinberg, 2008). Furthermore, the peptide has been used in high-throughput screening platforms to identify small molecule modulators of PKC, enabling the rapid assessment of compound efficacy and selectivity (Griner & Kazanietz, 2007).

Animal studies and ex vivo experiments have leveraged [Ser25] PKC (19-31) to probe PKC function in disease models. For example, administration of the peptide in rodent models of neurodegeneration resulted in modulation of synaptic plasticity and neuroprotection, supporting its relevance in translational research (Nelson & Alkon, 2009).

Usage Guidelines and Best Practices
For optimal results, [Ser25] PKC (19-31) should be reconstituted in sterile water or appropriate buffer at concentrations recommended by the manufacturer (typically 1-10 mM stock solutions). The peptide is stable at -20°C for long-term storage and should be aliquoted to avoid repeated freeze-thaw cycles.

In kinase assays, the peptide is typically used at a final concentration of 10-100 μM, depending on the specific PKC isoform and assay conditions. It can be employed as a substrate for in vitro phosphorylation assays, with detection by radiolabeling, mass spectrometry, or phospho-specific antibodies. As a competitive inhibitor, titration experiments are recommended to determine the optimal concentration for inhibition of endogenous PKC activity.

In cell-based assays, [Ser25] PKC (19-31) can be delivered via transfection, microinjection, or cell-permeable peptide derivatives. Careful optimization of delivery methods and controls is essential to ensure specificity and minimize off-target effects. The use of appropriate negative controls, such as scrambled peptides or non-phosphorylatable analogs, is strongly recommended.

Researchers should also consider the potential for peptide degradation by cellular proteases and employ prote Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 52 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11536852